FCX, an arylidene derivative, induces apoptosis in androgen receptor-selective prostate cancer cells
Conclusions: Together with the results, it is evident that FCX has a wide therapeutic window in the in vitro inhibition of the prostate cancer cells mediated by hormone-dependent effects.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Rajagopalan Prasanna Ashraf A Elbessoumy Harish C Chandramoorthy Ayed Dera Majed Al Fayi Source Type: research
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Estradiol | Hormones | Prostate Cancer | Statistics | Students | Study | Universities & Medical Training